Zevra announces arimoclomol featured in two poster presentations
PremiumThe FlyZevra announces arimoclomol featured in two poster presentations
2y ago
Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023
Premium
Press Releases
Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023
2y ago
Zevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium™ 2023
Premium
Press Releases
Zevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium™ 2023
2y ago
KemPharm Enhances Senior Management Team
PremiumPress ReleasesKemPharm Enhances Senior Management Team
2y ago
KemPharm CEO says positioned for ‘continued growth’
Premium
The Fly
KemPharm CEO says positioned for ‘continued growth’
2y ago
KemPharm Issues Letter to Shareholders
Premium
Press Releases
KemPharm Issues Letter to Shareholders
2y ago
KemPharm names Richard Pascoe as CEO
PremiumThe FlyKemPharm names Richard Pascoe as CEO
2y ago
KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease Company
Premium
Press Releases
KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease Company
2y ago
KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH)
Premium
Press Releases
KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH)
2y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100